Abstract: A biosensor device (10) for in situ monitoring of deep-water sea-floor biological patterns (30), which biosensor platform (10) comprises a plurality of cameras (12) and a lightening system (14), wherein a plurality of coral nubbins (16) with a plurality of polyps (18) are prepared and fixed to a platform (11) of the biosensor platform (10) with a distance to each other such that there is no overlap on a picture frame (22) thereof, and wherein the cameras (12) and the lightening system (14) are arranged so as to take coral-silhouette-pictures (CSP:s) of the plurality of nubbins (16) in the picture frame (22). In this way, there is provided a biosensor device based on coral, or other deep-sea species, behavioural for surveillance and monitoring of a deep-water sea-floor.

Abstract: A biosensor device (10) for in situ monitoring of deep-water sea-floor biological patterns (30), which biosensor platform (10) comprises a plurality of cameras (12) and a lightening system (14), wherein a plurality of coral nubbins (16) with a plurality of polyps (18) are prepared and fixed to a platform (11) of the biosensor platform (10) with a distance to each other such that there is no overlap on a picture frame (22) thereof, and wherein the cameras (12) and the lightening system (14) are arranged so as to take coral-silhouette-pictures (CSP:s) of the plurality of nubbins (16) in the picture frame (22). In this way, there is provided a biosensor device based on coral, or other deep-sea species, behavioural for surveillance and monitoring of a deep-water sea-floor.

Abstract: The present invention relates to new therapeutic and diagnostic uses of soluable neuregulin-1 isoforms and polypeptides, particularly neurological disorders.

Abstract: The present invention relates to new therapeutic and diagnostic uses of soluble neuregulin-1 isoforms and polypeptides, particularly neurological disorders.

Abstract: The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein of Klebsiella pneumoniae. The invention also relates to nucleotide sequences which encode these peptides or proteins and to the use of these sequences as a medicament. More particularly, such DNA sequences can be used in compositions which are intended for immunization by the intramuscular or intradermal route.

Abstract: A polypeptide useful as an immunogen element and characterised in that it is carried on the peptide sequence between amino acid residues 130–230 of the G protein sequence of the human respiratory syncytial virus of sub-groups A and B, or of the bovine respiratory syncytial virus, or on a sequence at least 80% homologous thereto. An immunogenic agent or pharmaceutical composition containing said polypeptide, and a method for preparing same, are also disclosed.

Abstract: A invention concerns a novel method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent, and polypeptides obtainable by said method. The invention also concerns the use of said polypeptides, in particular for preparing medicines or vaccines, for fighting against bacterial and viral infections or cancers.

Abstract: The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein of Klebsiella pneumoniae. The invention also relates to nucleotide sequences which encode these peptides or proteins and to the use of these sequences as a medicament. More particularly, such DNA sequences can be used in compositions which are intended for immunization by the intramuscular or intradermal route.

Abstract: A polypeptide useful as an immunogen element and characterised in that it is carried on the peptide sequence between amino acid residues 130-230 of the G protein sequence of the human respiratory syncytial virus of sub-groups A and B, or of the bovine respiratory syncytial virus, or on a sequence at least 80% homologous thereto. An immunogenic agent or pharmaceutical composition containing said polypeptide, and a method for preparing same, are also disclosed.

Abstract: The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein of Klebsiella pneumoniae. The invention also relates to nucleotide sequences which encode these peptides or proteins and to the use of these sequences as a medicament. More particularly, such DNA sequences can be used in compositions which are intended for immunization by the intramuscular or intradermal route.

Abstract: A polypeptide useful as an immunogen element and characterized in that it is carried on the peptide sequence between amino acid residues 130-230 of the G protein sequence of the human respiratory syncytial virus of sub-groups A and B, or of the bovine respiratory syncytial virus, or on a sequence at least 80% homologous thereto. An immunogenic agent or pharmaceutical composition containing said polypeptide, and methods for preparing and using the same, are also disclosed.

Abstract: A polypeptide useful as an immunogen element and characterised in that it is carried on the peptide sequence between amino acid residues 130-230 of the G protein sequence of the human respiratory syncytial virus of sub-groups A and B, or of the bovine respiratory syncytial virus, or on a sequence at least 80% homologous thereto. An immunogenic agent or pharmaceutical composition containing said polypeptide, and a method for preparing same, are also disclosed.

Abstract: A polypeptide useful as an immunogen element and characterized in that it is carried on the peptide sequence between amino acid residues 130-230 of the G protein sequence of the human respiratory syncytial virus of sub-groups A and B, or of the bovine respiratory syncytial virus, or on a sequence at least 80% homologous thereto. An immunogenic agent or pharmaceutical composition containing said polypeptide, and methods for preparing and using the same, are also disclosed.

Abstract: The invention concerns a novel method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent, and polypeptides obtainable by said method. The invention also concerns the use of said polypeptides, in particular for preparing medicines or vaccines, for fighting against bacterial and viral infections or cancers.

Abstract: A polypeptide useful as an immunogen element and characterized in that it is carried on the peptide sequence between amino acid residues 130-230 of the G protein sequence of the human respiratory syncytial virus of sub-groups A and B, or of the bovine respiratory syncytial virus, or on a sequence at least 80% homologous thereto. An immunogenic agent or pharmaceutical composition containing said polypeptide, and methods for preparing and using the same, are also disclosed.

Abstract: The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homology with the P40 protein of Klebsiella pneumoniae. The invention also relates to nucleotide sequences which encode these peptides or proteins and to the use of these sequences as a medicament. More particularly, such DNA sequences can be used in compositions which are intended for immunization by the intramuscular or intradermal route.

Abstract: A polypeptide useful as an immunogen element and characterized in that it is carried on the peptide sequence between amino acid residues 130-230 of the G protein sequence of the human respiratory syncytial virus of sub-groups A and B, or of the bovine respiratory syncytial virus, or on a sequence at least 80% homologous thereto. An immunogenic agent or pharmaceutical composition containing said polypeptide, and methods for preparing and using the same, are also disclosed.